THE USE OF INTRAVENOUS FORMS OF BETA-BLOCKERS IN ACUTE CORONARY SYNDROME
Abstract
Beta- blockers are actively used in the treatment of patients with chronic and acute ischemic heart disease. Throughout the study period of effects of beta-blockers to limit myocardial necrosis at acute myocardial infarction (AMI) clinical researches were performed under pharmacological reperfusion of the coronary arteries; herewith the data about the clinical efficacy of beta-blockers of the patients with invasive strategy treatment of AMI are limited in international literature. The purpose of this review is to analyze the world literature on the use of injection forms of beta-blockers in acute coronary syndrome. Based on the analysis, it was concluded that the intravenous administration of metoprolol in the acute period of myocardial infarction clearly leads to the restriction of the necrosis zone, reduces the risk of repeated myocardial infarction and reduces the incidence of ventricular fibrillation.
About the Authors
I. D. Astrakhantseva
State-Financed Organization Khanty-Mansi Autonomous Region - Ugra District Cardiodispensary «Centre of Diagnosis and Cardiovascular Surgery»
Russian Federation
Russian Federation
I. A. Urvantseva
State-Financed Organization Khanty-Mansi Autonomous Region - Ugra District Cardiodispensary «Centre of Diagnosis and Cardiovascular Surgery»
Russian Federation
Russian Federation
K. Yu. Nikolaev
Institute of Internal and Preventive Medicine
Russian Federation
Russian Federation
References
1. Frishman W.H. Beta-adrenergic blocking drugs // Am. Coll. Cardiol. Curr. J. Rev. 1997. Vol. 23.
2. Kaumann A.J. Some aspects of heart beta-adrenoceptor function // Cardiovasc. Drugs. Ther. 1991. Vol. 5. P. 549
3. Motomura S., Zerkowski H.R., Daul A. et al. On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies // Am. Heart J. 1990. Vol. 119. P. 608.
4. Gong H. et al. Specific beta2 AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta 2 AR in myocytes from failing human heart // Circulation. 2002. Vol. 105. P. 2497-2503.
5. Cruickshank J.M., Prichard B.N.C. Beta-adrenoceptors // Beta-blockers in clinical practice. London: Churchill Livingstone, 1996. P. 9-86.
6. Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta Blockers of the European Society of Cardiology // Eur. Heart J. 2004. Vol. 25. P. 1341-1362.
7. Ярохно Н.Н., Бондарева З.Г., Николаев К.Ю. Острый инфаркт миокарда: новые возможности ранней диагностики, лечения и прогноза. Новосибирск: Сибмедиздат НГМУ, 2011. 200 с.
8. The Norwegian Multicenter Study Grooup. Timolol-induced reduction in mortality and reinfarction inpatients surviving acute myocardial infarction // N. Engl. J. Med. 1981. Vol. 304. P. 801-807.
9. Beta-Blocker Heart Attack Trial Reseach Group. A randomized trial of propranoloi in patients with acute myocardial infarction. L Mortality results // JAMA. 1982. Vol. 247. P. 1707-1714.
10. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blocade on mortality among high-risk and low-risk patients after myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. P. 489-497.
11. First International Study of Infarct Survival Collaborative Group Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 // Lancet. 1986. Vol. 2. P. 57-66.
12. Hjalmarson A., Elmfeldt D., Herlitz J. et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blindrandomisedtrial // Lancet. 1981. Vol. 2. P. 823-827.
13. Norris R.M., Barnaby P.F., Brown M.A. et al. Prevention of ventricularfibrillation during acute myocardial infarction by intravenous pro-pranolol // Lancet. 1984. Vol. 2. P. 883-886.
14. Chen Z.M., Pan H.C., Chen Y.P. et al. Early intravenous than oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial // Lancet. 2005. Vol. 366. P. 1622-1632.
15. Vande Werf F., Bax J., Betriu A. et al. Management of acutemyocardial infarction in patients presenting with persistent ST-segment elevation:The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology // Eur. Heart J. 2008. Vol. 29. P. 2909-2945.
16. Antman E.M., Hand M., Armstrong P.W. et al. 2007 focusedupdate of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. 2008. Vol. 51. P. 210-247.
17. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial // Eur. Heart J. 1985. Vol. 6. P. 199-226.
18. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 (First International Study of Infarct Survival) Collaborative Group // Lancet. 1986. Vol. 2. P. 57-66.
19. Roberts R., Rogers W.J., Mueller H.S. et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study // Circulation. 1991. Vol. 83. P. 422-437.
20. Pfisterer M., Cox J.L., Granger C.B., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA Alteplase) for Occluded Coronary Arteries // J. Am. Coll. Cardiol. 1988. Vol. 32. P. 634-640.
21. Prasad A., Stone G.W., Aymong E. et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial // Am. Heart J. 2004. Vol. 147. P. 669-675.
22. Halkin A., Grines C.L., Cox D.A. et al. Impact of intravenous beta-blockade before primary angio- plasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction // J. Am. Coll. Cardiol. 2004. Vol. 43. P. 1780-1787.
23. Valle J.A., Zhang M., Dixon S. et al. Impact of pre-procedural beta-blockade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction // Am. J. Cardiol. 2013. Vol. 111. P. 1714-1720.
24. Sharma S.K., Kini A., Marmur J.D., Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival // Circulation. 2000. Vol. 102. P. 166-172.
25. Ellis S.G., Brener S.J., Lincoff A.M. et al. Beta-blockers before percutaneous coronary intervention do not attenuate postproceduralcreatine kinase isoenzyme rise // Circulation. 2001. Vol. 104. P. 2685-2688.
26. Ibanez B., Cimmino G., Prat-González S. et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion // Int. J. Cardiol. 2011. Vol. 147. P. 428-432.
27. Ndrepepa G., Kastrati A. Intravenous Β-Blockers in Primary Percutaneous Coronary Intervention: New Hope for an Old Therapy // Circulation. 2013. Vol. 128. P. 1487-1489.
28. Ibanez B., Macaya C., Sánchez-Brunete V. et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial // Circulation. 2013. Vol. 128. P. 1495-1503.
Review
For citations:
Astrakhantseva I.D., Urvantseva I.A., Nikolaev K.Yu. THE USE OF INTRAVENOUS FORMS OF BETA-BLOCKERS IN ACUTE CORONARY SYNDROME. Ateroscleroz. 2017;13(2):50-54. (In Russ.)
Views:
1417
Email this article 